{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.976","upperLimit":"0.998","value":"0.987"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"406"}],"units":"Participants"}],"description":"Disease-free survival (DFS) is the proportion of participants ramaing disease free at 3 years based on the Kaplan-Meier method. DFS is defined to end at the time of the first of the following events: local/regional ipsilateral invasive recurrence (or ipsilateral invasive new primary), contralateral invasive breast cancer, distant recurrence, or death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"80 mg of paclitaxel per square meter of body-surface area weekly for 12 weeks and a loading dose of 4 mg of intravenous trastuzumab per kilogram of body weight on day 1, followed by 2 mg per kilogram weekly, for a total of 12 doses. After the completion of 12 weeks of treatment with Trastuzumab.\n\nTrastuzumab 6mg/kg over 3 weeks to complete a full year of intravenous treatment with trastuzumab.","id":"OG000","title":"Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"at 3 years","title":"3-year Disease Free Survival (DFS) Rate","type":"PRIMARY","unitOfMeasure":"proportion of participant"}